Legend Biotech Corporation Fundamental Analysis (NASDAQ: LEGN)
Legend Biotech Corporation (NASDAQ: LEGN) shows moderate financial fundamentals with a PE ratio of -65.29, profit margin of -0.02%, and ROE of -0.02%. The company generates $1.4B in annual revenue with strong year-over-year growth of 64.04%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.1/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze LEGN's fundamental strength across five key dimensions:
Efficiency Score
WeakLEGN struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLEGN trades at attractive valuation levels.
Growth Score
ModerateLEGN shows steady but slowing expansion.
Financial Health Score
ExcellentLEGN maintains a strong and stable balance sheet.
Profitability Score
WeakLEGN struggles to sustain strong margins.
Key Financial Metrics
Is LEGN Expensive or Cheap?
P/E Ratio
LEGN trades at -65.29 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LEGN's PEG of -0.64 indicates potential undervaluation.
Price to Book
The market values Legend Biotech Corporation at 2.76 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 38.12 times EBITDA. This signals the market has high growth expectations.
How Well Does LEGN Make Money?
Net Profit Margin
For every $100 in sales, Legend Biotech Corporation keeps $-0.02 as profit after all expenses.
Operating Margin
Core operations generate 2.51 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.02 in profit for every $100 of shareholder equity.
ROA
Legend Biotech Corporation generates $-0.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Legend Biotech Corporation generates limited operating cash flow of $-247.07M, signaling weaker underlying cash strength.
Free Cash Flow
Legend Biotech Corporation generates weak or negative free cash flow of $-319.93M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.73 in free cash annually.
FCF Yield
LEGN converts -8.98% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-65.29
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.64
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.76
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.58
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.95
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.00
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How LEGN Stacks Against Its Sector Peers
| Metric | LEGN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -65.29 | 31.66 | Better (Cheaper) |
| ROE | -0.02% | 501.00% | Weak |
| Net Margin | -0.02% | -3647.00% (disorted) | Weak |
| Debt/Equity | 0.13 | -0.30 (disorted) | Distorted |
| Current Ratio | 3.95 | 5.78 | Strong Liquidity |
| ROA | -0.01% | -262.00% (disorted) | Weak |
LEGN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Legend Biotech Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
779.39%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
28.58%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
71.12%
Industry Style: Defensive, Growth, Innovation
High Growth